Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.

The Journal of antimicrobial chemotherapy - 1 Jan 2014

Calcagno Andrea, Cusato Jessica, Simiele Marco, Motta Ilaria, Audagnotto Sabrina, Bracchi Margherita, D'Avolio Antonio, Di Perri Giovanni, Bonora Stefano

Abstract excerpt

OBJECTIVES: To analyse the determinants of raltegravir CSF penetration, including the pharmacogenetics of drug transporters located at the blood-brain barrier or blood-CSF barrier. METHODS: Plasma and CSF raltegravir concentrations were determined by a validated HPLC coupled with mass spectrometr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Blood-Brain Barrier
Share to Cerebrospinal Fluid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Multidrug Resistance-Associated Protein 2

Share to Plasma

Share to Pyrrolidinones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 23975735
DOI: 10.1093/jac/dkt339

Genes

ABCB1
ABCC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23975735-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.PMID 23975735Read ↗

Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study.Semantic proximity Read ↗

Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.Semantic proximity Read ↗

Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants.Semantic proximity Read ↗

Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments.Semantic proximity Read ↗

Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations.Semantic proximity Read ↗

Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency VirusSemantic proximity Read ↗

Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.Semantic proximity Read ↗

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.Semantic proximity Read ↗

Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.Semantic proximity Read ↗

Host single nucleotide polymorphisms and biomarkers of neuronal damage and inflammation in people living with HIV.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.